secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-07-19T23:59:59+00:00
Accession:  0001683168-22-005036
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte reports positive interim results in malignant ascites mouse model study
--------------------------------------------------------------------------------

- Study conducted by Heidelberg Pharma using colon carcinoma cells from Austrianova Master Cell Bank in mice.
- Initial data indicates overall tumor volume (Sugarbaker-index) more accurate than fluorescence for tumor burden.
- Objectives include optimizing tumor cell dose, timing curve, and assessment method.
- CEO Kenneth Waggoner says study proceeding as hoped; confident all objectives will be achieved.
- Malignant ascites has no approved treatment; therapy aims to slow or eliminate fluid accumulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005036/0001683168-22-005036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822005036/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-005036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer